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ing author. Tel.: +44 141
ess: kskeldon@physics.gSummary There is increasing interest in ethane (C2H6) in exhaled breath as a non-
invasive marker of oxidative stress (OS) and thereby a potential indicator of disease.
However, the lack of real-time measurement techniques has limited progress in the
field. Here we report on a novel Tunable Diode Laser Spectrometer (TDLS) applied to
the analysis of exhaled ethane in patients with lung cancer. The patient group
(n ¼ 52) comprised randomly selected patients presenting at a respiratory clinic. Of
these, a sub-group (n ¼ 12) was subsequently diagnosed with lung cancer. An age-
matched group (n ¼ 12) corresponding to the lung cancer group was taken from a
larger control group of healthy adults (n ¼ 58). The concentration of ethane in a
single exhaled breath sample collected from all subjects was later measured using
the TDLS. This technique is capable of real-time analysis of samples with accuracy
0.1 parts per billion (ppb), over 10 times less than typical ambient levels in the
northern hemisphere.
After correcting for ambient background, ethane in the control group (26%
smokers) ranged from 0 to 10.54 ppb (median of 1.9 ppb) while ethane in the lung
cancer patients (42% smokers) ranged from 0 to 7.6 ppb (median of 0.7 ppb). Ethane
among the non-lung cancer patients presenting for investigation of respiratory
disease ranged from 0 to 25 ppb (median 1.45 ppb).Elsevier Ltd. All rights reserved.
330 2047; fax: +44 141 330 2893.
la.ac.uk (K.D. Skeldon).
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Exhaled ethane and lung cancer 301We conclude that, while the TDLS proved effective for accurate and rapid sample
analysis, there was no significant difference in exhaled ethane among any of the
subject groups. Comments are made on the suitability of the technique for
monitoring applications.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Exhaled ethane is produced in vivo by the oxidation
of cell membrane lipids1 which occurs as a
consequence of free-radical-mediated attack.2
Antioxidant defences counter free-radical attack
resulting in a state of equilibrium in healthy
individuals. Oxidative stress (OS) was defined in
1985 as ‘a disturbance in the pro-oxidant/antiox-
idant balance in favour of the former’.3 While the
precise role of OS in the pathogenesis of disease is
unclear, it has been widely recognised as a
contributory factor4 with extreme levels of OS
being associated with critical illness5 and even-
tually contributing to organ failure.6 Considerable
evidence supports the hypothesis that an increased
level of OS is associated with lung cancer. Zieba
demonstrated increased concentrations of markers
of OS (conjugated dienes, thiobarbituric acid
reacting substances, Schiff bases, and lipid hydro-
peroxides) in tumour tissue homogenates compared
to lung parenchyma, in patients with lung cancer.7,8
Tumour tissue samples taken from patients with
pulmonary adenocarcinoma and squamous cell
carcinoma showed striking alterations in antioxi-
dant capacity consistent with increased levels of
OS, compared with tumour-free lung parenchymal
tissues from the same individuals.9
Given that ethane is believed to be produced in
vivo solely by the process of lipid peroxidation, it is
metabolised slowly10 and it is poorly soluble in body
fat,11 it makes an ideal breath biomarker for OS.12
Previous studies have demonstrated increased
ethane exhalation in human patients with respira-
tory disease, airway inflammation and other con-
ditions.13–15 However, the study of volatile organic
compounds (VOCs) in the exhaled breath of lung
cancer patients has focussed on the hydrocarbons
in the range C4–C2016,17 possibly due to the
difficulties in trapping and measuring ethane (C2)
at the parts per billion (ppb) level. Having said this,
the majority of groups studying exhaled ethane
employ variants of gas chromatography (GC) some-
times coupled with mass spectrometry. This is
undeniably the accepted gold standard for VOC
measurement in breath analysis, and a technique
we have employed in some of our own studies in the
past.18 However, where ethane is concerned at ppblevels the GC-based technique requires pre-con-
centration of the breath exhalate and the time
taken to measure a single sample is typically more
than half-an-hour, even in an automated system. In
contrast (and an important advantage in the
present study) is that our spectroscopy technique
offers baseline sensitivity of 0.1 ppb and, moreover,
this accuracy is achieved essentially in real-time,
making for swift measurement of breath samples.
The recent availability of such optical spectroscopy
systems for gas concentration analysis promises to
open up new opportunities for the application of
the ethane breath test for assessment of OS in
medicine.19–23
The aims of this study were: (i) to investigate the
feasibility of applying a novel laser spectrometer
(Tunable Diode Laser Spectrometer (TDLS)) shown
in Fig. 1 to the analysis of clinical breath samples;
and (ii) to investigate the association between
exhaled ethane and lung cancer. This study was
approved by the NHS Tayside Regional Ethics
Committee.Materials and methods
Participants
Patients
Fifty-two patients (age 66713 years, mean7SD),
newly referred to Ninewells Hospital for evaluation
of respiratory disease were prospectively included
in this study (Group 1). Being newly referred,
patients had not received any medication prior
to providing breath samples. Other inclusion
criteria were: aged 18 or older, comprehension of
the breath-collection procedure and signed in-
formed consent. Otherwise, patients were essen-
tially selected at random, being those who
happened to have appointments on the days set
aside for sample collection. Consequently, males
and females were included and both smokers and
non-smokers.
Twelve of the patients (age 70710 years,
mean7SD) were subsequently confirmed to have
lung cancer (Group 2) diagnosed by biopsy of
bronchus or cytology of bronchial brushings sup-
ported by clinical features of lung cancer.
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Figure 1 Photograph of the TDLS system used in this study. The instrument offers a real-time output for ethane
concentration making it ideal for direct subject access (as shown) or alternatively, as in the study described here, it can
be applied to the analysis of remotely collected sample bags. The fast turnaround of measurements (10 s per sample
bag) combined with the baseline sensitivity of 0.1 ppb offer unprecedented access to accurate and reliable breath
ethane assessment.
K.D. Skeldon et al.302Control subjects
Fifty-eight healthy volunteer subjects (age 69711
years, mean7SD) were also recruited for participa-
tion in this study (Group 3). The control group
reported themselves to be in good health and free
of medication. A sub-group (69710 years,
mean7SD) of this control group was selected as
an age-matched control set (Group 4) for the lung
cancer patients.Study design
A single breath sample was collected from each
patient presenting at the Respiratory clinic, and
from each control subject. At the same time,
corresponding samples of the background air were
collected. The collection of breath samples was
standardised by following a consistent protocol.
Subjects were instructed to breathe normally and to
start providing the sample at the top of the normal
inhalation (that is, without taking a deep breath
and ‘diluting’ the sample with excessive room air)
and exhaling as fully as possible into a 5 l gas-
impermeable sample bag (Tedlar, SKC Limited).
Prior to providing the sample, subjects were
required to remain in the collection venue for at
least 30min to ensure consistent and thorough
equilibration with the test room environment. The
concentration of ethane in the exhaled breath ofSKC Limited, Blandford Forum, Dorset, UK.each subject was calculated as the difference
between the measured concentration in their
sample and the corresponding background sample.
We have verified that this technique provides a
comparable method of consistent sample collection
as compared with prior inhalation of hydrocarbon-
free air—techniques that are generally accepted in
the literature as achieving reproducible breath
sample exhalates.19 To further standardise the
sampling protocol, patients were asked about
possible interfering agents such as cigarette smok-
ing and food and drink consumption. In all the
patients accepted into the trial numbers, at least an
hour had passed since the last cigarette and several
hours since the last meal (typically breakfast) and
at least 12 h since their last alcoholic drink.
Measurement of the ethane in the sample bags
was inevitably delayed since samples were col-
lected at some distance from the TDLS. However,
measurement was typically done within 1–3 days
after collection in order to avoid errors due to any
diffusion through the wall of the bag. Measure-
ments made of empirically mixed ethane in nitro-
gen concentrations using the TDLS show the storage
integrity of the sampling bags to be satisfactory
over the course of a week (10% alteration in
concentration).Laser spectroscopy measurement technique
Breath ethane was measured using an ultra-
sensitive laser absorption spectroscopy technique
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Figure 2 Column chart showing the basic calibration
accuracy of the ethane spectroscopy system operating in
two independent modes: scanning, where the laser is
frequency scanned over the ethane transition allowing
potential interfering contaminants to be checked, and
line-locked, where the laser wavelength is exactly tuned
to the ethane absorption. In both cases, the output of the
instrument is for a set of empirical ethane concentrations
is examined. The ethane mixes are obtained from a
certified ethane standard (BOC Edwards 52.4 ppm71%)
mixed with hydrocarbon-free nitrogen (etha-
neo0.1 ppb).
Exhaled ethane and lung cancer 303developed at the University of Glasgow, motivated
primarily for analysis of ethane in an industrial
application20 and more recently redesigned for use
in healthcare applications.21 The spectroscopic
technique uses a lead-salt tunable diode laser
operating at 3.4 mm where there is a densely
populated set of ethane absorption transitions.
Moreover, we choose a specific absorption line
within this range that is free from potential
interfering species such as water and carbon
dioxide. The measurement technique involves
passing the laser light through a sample cell that
imposes multiple reflections on the beam to create
a 170m optical path length. Breath samples are
drawn through this cell by an oil-free scroll pump
and the absorption of the laser light at the ethane
transition is measured by a photodetector and
analysed using a laptop-controlled modulation
scheme. The instrument is continually calibrated
against a known ethane standard and checked for
good zero performance every 60 s by flushing the
measurement cell hydrocarbon-free nitrogen gas
(ethaneo0.1 ppb). Full technical details of the
spectroscopy system along with a more compre-
hensive appraisal of the competing optical tech-
nologies can be found in Skeldon et al.21 The end
result is a sensitivity to ethane gas of 0.1 ppb over a
1 s sampling period, and an absolute accuracy of
better than 10% when compared against certified
empirical standards as shown in Fig. 2. The
performance of the instrument is in the process of
being validated against gas chromatography–mass
spectrometry (GC–MS) in order to afford a greater
degree of medical acceptance; however, the
measurement technique is absolute, based as it is
on absolute sub-atomic optical transitions within
the ethane molecules. The empirical comparison in
Fig. 2 is intended to strengthen the confidence in
this technique for the study presented, given that
optical measurement techniques still underpin an
extremely small minority of studies in the breath
analysis field, with GC–MS forming the gold
standard.
In terms of measuring the patients’ ethane
levels, the sample bags were attached to the input
port of the system and the gas drawn through the
sample cell at a flow rate of 5 l/min. The laptop
automation of the instrument affords an efficient
measurement turnaround (around 12 s per sample)
and convenient storage of data for later analysis.Data analysis
Data are presented as mean7SD, or median
(range). The data was plotted on a histogram andfound not to confirm to the parameters of the
normal distribution. Significance testing was per-
formed using a Mann–Whitney test for non-para-
metric data. A Spearman rank correlation
coefficient was used to describe the relationship
between age and ethane. Statistical significance
was accepted at Po0:05.Results
Ethane exhalation in the control subjects ranged
from 0 to 10.54 ppb, median 1.9 ppb, and 26% of
the control subjects were smokers. Ethane exhala-
tion in the lung cancer patients ranged from
0–7.6 ppb, median 0.7 ppb, and 42% of cancer
patients were smokers. Ethane exhalation among
the non-lung cancer patients presenting for inves-
tigation of respiratory disease was 0–25 ppb,
median 1.45 ppb, and 38% of these patients were
smokers (Fig. 3). There was no significant differ-
ence between ethane exhalation among the control
subjects (Group 3), patients presenting at the
respiratory clinic (Group 1) or lung cancer patients
(Group 2). Similarly, there was no significant
difference between ethane exhalation in lung
cancer patients and age-matched subjects paired
ARTICLE IN PRESS
Et
ha
ne
 (p
pb
)
Healthy
Controls
Respiratory
Patients
Lung Cancer
Patients
0
2
4
6
8
10
12
Figure 3 Box and whisker plot illustrating the distribu-
tion of data for exhaled ethane among the subjects in this
study. The line across the box is the median, the bottom
of the box is the first quartile (Q1) and the top is the third
quartile (Q3). The whiskers are the lines that extend
from the top of the box defined by the upper limit Q1+1.5
(Q3—Q1). Outliers are points outside the upper limits,
plotted with open circles. (Outliers of 25 ppb and 21 ppb
for control and respiratory disease group respectively are
not shown.)
K.D. Skeldon et al.304from the control group (Group 4). Interestingly,
there was no significant correlation between age
and ethane exhalation.Discussion
In relation to the first aim of the study, the
application of laser spectroscopy was found to
facilitate rapid, accurate and reliable analysis of
ethane in exhaled breath. Exhaled ethane concen-
trations are typically of the order of a few ppb
(1:109) and this technique is consistently accurate
to a further order of magnitude; that is 7 0.1 ppb.
Part of the reason for performing the study was
to investigate the practicalities of implementing an
ethane breath test in an environment where the
ambient ethane may be much increased, for
example due to cleaning fluids and other chemical
contaminants. However, we were reassured to find
low background values during the study, with the
range measured from the clinic waiting area and
consulting rooms being 0.6–3.6 ppb (1.871.1,
mean7SD).
In terms of the technology, laser spectroscopy
generally has a number of advantages over current
methods to measure exhaled ethane such as
gas chromatography–flame ionisation detection(GC–FID) or GC–MS. As discussed earlier these
methods are often laborious and time-consuming
and, while they are more widely available, they are
generally not sensitive to ethane at ppb level so
that a gas concentration phase and sample pre-
paration phase is usually necessary. These require-
ments add to the complexity and expense of the
ethane assay. Selected ion flow tube (SIFT) tech-
nology, though capable of ppb detection of the
most abundant breath gases, is unsuitable for
ethane detection due to the lack of a dipole
moment in the ethane molecule. Finally, we should
point out that mirror contamination in our optical
technique does not degrade sensitivity via optical
path length reduction, unlike the competing
technique of cavity-ring down-spectroscopy.22,23
Mirror coatings are particularly vulnerable to
degradation in healthcare applications where high
levels of water vapour are typically present in a
sample.
In contrast, the laser spectrometer in this
study is set up to scan over a short range in
wavelength (only 0.2 nm compared with the ab-
sorption wavelength of 3400 nm) and this optical
selectivity means that this technique is highly
specific for ethane detection. Thus no sample
preparation phase is required and this facilitates
sensitive (0.1 ppb), rapid, indeed real-time, analy-
sis of breath samples, making this method
eminently suitable for the application of the
ethane breath test and the assessment of OS in
medicine.
In terms of the clinical application of this
approach, the ethane breath test has one main
advantage over other methods currently used to
assess OS: it is entirely non-invasive. It was
noteworthy that 100% of respiratory patients
(Group 1) who agreed to participate were able to
provide a sample without difficulty. This is not
typical since other pulmonary function tests often
require manipulation of the respiratory pattern
that patients with respiratory disease can find
difficult.
The second aim of the study was to define the
relationship between the concentration of exhaled
ethane and the presence of lung cancer. This study
clearly shows that there is no significant increase in
the concentration of exhaled ethane in patients
with lung cancer and that ethane is not specifically
associated with lung cancer.
The small numbers of patients with lung cancer
included in this study precludes detailed analysis
of the significance of OS in lung cancer. However,
the results presented here indicate that lung
cancer was not accompanied by a significant
increase in exhaled ethane, and that considerable
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Exhaled ethane and lung cancer 305variation existed in breath ethane levels in
healthy controls. Taken together, these findings
suggest that a single measurement of breath
ethane from individual patients is unlikely to
provide any useful clinical information. The poten-
tial application of serial measurements of breath
ethane in individual patients requires further
evaluation.
Having said this, additional measurements made
following single control subjects (n ¼ 5) shows the
reproducibility of background corrected ethane in
breath to be relatively stable (1.471.2 ppb,
mean7SD) and typically much lower than the
spread across the various groups in this study. A
typical result is shown in Fig. 4.
Although the study demonstrates a null correla-
tion between exhaled ethane levels and the
physical presence of disease, we feel it is an
important result particularly within the current
climate of interest in OS and its relationship with
disease. While it may well be the case that
multiple-VOC breath analysis represents a useful
clinical indicator, the results of the present study
taken alongside the general acceptance of ethane
as the best breath biomarker of OS, suggest that
other processes giving rise to patterns of breath
exhalates are implicated. Indeed, on the basis of
the findings here, OS may well not be the dominant
process that gives rise to a clinically useful breath
analysis indicator. Ultimately, the clinical implica-
tions will become clearer as studies continue in
the breath analysis field and we would suggest that0
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Figure 4 A typical longitudinal reproducibility plot for a
control subject (female, 68 years). Exhaled breath
samples and ambient background samples were collected
daily in the late afternoon and later analysed with the
TDLS. The top plot shows the uncorrected breath ethane
concentrations and the lower plot shows the concentra-
tions less background. The values relate to the mean and
standard deviation for each data set. For each measure-
ment the subject remained in the same environment for
at least 12 h.null results are as significant as positive correla-
tions in steering the direction of clinical trials
and their interpretation. However, while the
diagnostic applications of the ethane breath test
as a marker for OS may be limited by noise factors
outwith convenient clinical control, there re-
mains exciting potential for longitudinal monitoring
opportunities where a non-invasive measure of
OS can bring significant value. To this end, we
are currently engaged in pilot studies in trans-
plantation and radiotherapy and have completed
the first cross-species exercise-induced OS
study showing ethane to be a credible real-time
biomarker.24Conclusion
The TDLS approach proved to be effective and
reliable, providing a real-time output of ethane
concentration with a baseline sensitivity far
in excess of what is practically required (0.1 ppb).
However, the results of the study do not
support the application of the ethane breath
test for detection of lung cancer, as levels of
exhaled ethane in lung cancer patients were
not significantly different from either age-
matched healthy controls, or patients presenting
for evaluation of respiratory diseases other than
lung cancer. OS is a ubiquitous biochemical
process that accompanies most pathological pro-
cesses. The assessment of such a non-specific
cellular event is unlikely to be useful in
the diagnosis of any pathological condition. On
the other hand, the assessment and monitoring
of OS might be expected to be a sensitive
method for longitudinal monitoring of individual
patients, to assess their response to therapy
and disease progression. It is therefore in this
context, in fields such as critical care and trans-
plantation medicine for example, that the TDLS
technique would seem to offer the possibility of
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